Varian Introduces IntelliBlate in Europe, Advancing an Integrated Microwave Ablation Solution for Image-Guided Cancer Therapy
Designed to provide clinicians with greater predictability, precision, and control, IntelliBlate serves as the cornerstone of a future-focused, integrated ecosystem for microwave ablation. This therapeutic device complements the Siemens Healthineers' suite of imaging and software solutions including: myAblation Guide for planning and post-procedural confirmation software, myNeedle Laser guidance system that enhances placement with a CT scan, and ultrasound for assessment, placement, and monitoring during treatment. With the addition of IntelliBlate, the Varian and Siemens Healthineers' offerings allow clinicians to plan, place, treat, monitor, and confirm ablation therapy in one environment, simplifying workflow and supporting greater confidence in targeting and treatment.
IntelliBlate delivers the versatility to meet the unique clinical needs of each patient. It produces large, controlled spherical ablation zones for predictable treatment delivery. A novel feature, the Ximitry probe's thermocouples provide continuous temperature monitoring inside and outside the ablation zone, allowing clinicians to observe real-time temperature changes and make informed decisions.
The system provides two generators in one system making it compact and portable. The intuitive interface with fast set up and pre-programmed ablation zone settings makes the IntelliBlate a streamlined solution that helps reduce procedural barriers.
Following receipt of its U.S. FDA market clearance in 2024, IntelliBlate enters the European market at a time of growing clinical evidence around thermal ablation. The COLLISION trial 1, a large international phase 3 study, published in The Lancet Oncology, demonstrated that thermal ablation can be as effective as the gold standard, surgical resection alone, in treating small-size colorectal liver metastases (CRLM) while resulting in significantly fewer complications, comparable overall survival, and shorter hospital stays for patients.
'The results of the COLLISION trial mark a milestone in how we think about ablation,' said Franck Facchini, President of Interventional Solutions at Varian. 'We have reached the point where the clinical evidence unrefutably supports the use of thermal ablation as a first-line treatment option, and not just an option for patients who cannot undergo surgery. IntelliBlate was designed to meet this shift in care, combining precision with intelligent software and imaging in a solution that fits seamlessly into modern cancer care workflows.'
IntelliBlate will be introduced to the European clinical community in September at CIRSE 2025, the leading European Congress for interventional radiology in which Varian and Siemens Healthineers will offer hands-on demonstrations and educational sessions to support training, best practice and early clinical adoption.
IntelliBlate represents a more targeted, less invasive approach to cancer care, offering new options to clinicians and new hope to patients. It reflects Varian's commitment and investment to becoming a leading innovator in interventional solutions and envisioning a world without the fear of cancer. Varian's journey with Siemens Healthineers is just getting started; together, we are committed to the continued development of a smart, integrated approach that connects innovative therapy technologies and image-guided solutions.
© 2025 VARIAN MEDICAL SYSTEMS, INC. All trademarks are the property of their respective owners.
About Varian
At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 75 years, Varian has developed, built, and delivered innovative technologies and solutions that help care providers around the globe treat millions of patients each year. Today, as a Siemens Healthineers company, we support every step of the cancer care journey – from screening to survivorship. From advanced imaging and radiation therapy to comprehensive software and services, to interventional radiology, we are harnessing the power of our perspective while also pursuing clinical research to create a more efficient, and more personalized care pathway. Because, for cancer patients everywhere, their fight is our fight. For more information, visit http://www.varian.com.
QR700024726
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
18 minutes ago
- Business Wire
Deadline Soon: 3D Systems Corporation (DDD) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
LOS ANGELES--(BUSINESS WIRE)-- The Law Offices of Frank R. Cruz reminds investors of the upcoming deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired 3D Systems Corporation ('3D Systems' or the 'Company') (NYSE: DDD) securities between August 13, 2024 and May 12, 2025, inclusive (the 'Class Period'). IF YOU ARE AN INVESTOR WHO LOST MONEY ON 3D SYSTEMS CORPORATION (DDD), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT. What Happened? On March 26, 2025, 3D Systems released its fourth quarter and full year 2024 financial results, missing consensus estimates in non-GAAP earnings-per-share and sales revenue, citing 'lowers hardware systems sales due to macroeconomic factors that are negatively impacting demand.' The Company also reported a '$9 million revenue reduction in Q4 driven by a change in accounting estimates for [the Company's] Regenerative Medicine program." The Company disclosed that "[t]his change in estimate [was] related to the now anticipated use of pre-clinical human decedent testing . . . which led to refinement of the milestone technical criteria." On this news, 3D Systems' stock price fell $0.57, or 21%, to close at $2.15 per share on March 27, 2025, thereby injuring investors. Then, on May 12, 2025, after market hours, 3D Systems released its first quarter 2025 financial results, missing consensus estimates due, in part, to a decline in material sales, mostly due to inventory management issues in the dental portion of its Healthcare Solutions segment. The Company further disclosed that it was withdrawing its full-year 2025 outlook, citing prolonged softness in customer capital spending and macroeconomic uncertainty. On this news, 3D Systems' stock price fell $0.68, or 26.6%, to close at $1.87 per share on May 13, 2025, thereby injuring investors further. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) 3D Systems had understated the impact of weakened customer spending on the Company's business, while overstating its resilience in challenging industry conditions; (2) the updated milestone criteria in the United Partnership would negatively impact the Company's Regenerative Medicine Program revenue; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired 3D Systems securities between August 13, 2024 and May 12, 2025, the deadline to seek appointment as the lead plaintiff in the securities fraud class action is August 12, 2025. Contact Us To Participate or Learn More: If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact us: Frank R. Cruz The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 Email us at: info@ Call us at: 310-914-5007 Visit our website at Follow us for updates on Twitter: If you inquire by email, please include your mailing address, telephone number, and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
18 minutes ago
- Business Wire
Deadline Soon: Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
LOS ANGELES--(BUSINESS WIRE)-- The Law Offices of Frank R. Cruz reminds investors of the upcoming August 11, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Rocket Pharmaceuticals, Inc. ('Rocket' or the 'Company') (NASDAQ: RCKT) securities between , inclusive (the 'Class Period'). IF YOU ARE AN INVESTOR WHO LOST MONEY ON ROCKET PHARMACEUTICALS, INC. (RCKT), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT. What Happened? On May 27, 2025, Rocket disclosed that the FDA had placed a clinical hold on the Phase 2 pivotal trial of its Danon disease treatment, RP-A501, after at least one patient died following a substantive amendment to the protocol that the Company had not disclosed until after the Serious Adverse Event ('SAE') occurred. On this news, Rocket's stock price fell $3.94, or 62.8%, to close at $2.33 per share on May 27, 2025, thereby injuring investors. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Rocket knew SAEs, including death of participants enrolled in the study, were a risk; (2) Rocket amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Rocket securities between September 17, 2024 and May 26, 2025, the deadline to seek appointment as the lead plaintiff in the securities fraud class action is August 11, 2025. Contact Us To Participate or Learn More: If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact us: Frank R. Cruz The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 Email us at: info@ Call us at: 310-914-5007 Visit our website at Follow us for updates on Twitter: If you inquire by email, please include your mailing address, telephone number, and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
18 minutes ago
- Business Wire
Deadline Approaching: Novo Nordisk A/S (NVO) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Novo Nordisk A/S ('Novo Nordisk' or the 'Company') (NYSE: NVO) securities between May 7, 2025, to July 28, 2025, inclusive (the 'Class Period'). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN NOVO NORDISK A/S (NVO), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On July 29, 2025, Novo Nordisk cut its previously issued fiscal year 2025 guidance, lowering sales growth from 13-21% to 8-14%, and operating profit from 16-24% to 10-16%. The Company cited lower growth expectations for both Ozempic and Wegovy on the back of a slowdown in market expansion, competition, and the alleged continued use of compounded GLP-1s. On this news, Novo Nordisk's stock price fell $15.06, or 21.8%, to close at $53.94 per share on July 29, 2025, thereby injuring investors. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Novo Nordisk repeatedly ignored and minimized the significance of the personalization exception for GLP-1 compounding, greatly overestimated its ability to capture patients coming off of compounded treatments, and was ultimately ill equipped to capitalize upon the purported significant unmet patient population; and (2) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Novo Nordisk securities during the Class Period, you may move the Court no later than September 30, 2025 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. Contact Us To Participate or Learn More: If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
